DeutschNewstral
Article
jdsupra.com on 2018-10-18 23:40
President Signs Bill Requiring FTC and DOJ Review of Biosimilar Patent Litigation Settlements
Related news
- Senate Passes MMA Amendment Requiring FTC and DOJ Review of Biosimilar Patent Litigation Settlementsjdsupra.com
- House Passes MMA Amendment Requiring FTC and DOJ Review of Biosimilar Patent Litigation Settlementsjdsupra.com
- Bill Requiring Disclosure of Biosimilar Settlement Agreements to the FTC and DOJ Becomes Lawjdsupra.com
- Senators Ask FTC to Investigate Biosimilar Litigation Settlement Agreementjdsupra.com
- Biologic and Biosimilar Settlement Agreements Now Must Be Disclosed to DOJ and FTCjdsupra.com
- FTC Report on Patent Assertion Entities Recommends Patent Litigation Reformjdsupra.com
- Biologic and Biosimilar Litigation Updatesjdsupra.com
- Biosimilar-Related Patent Litigation Updatesjdsupra.com
- ANDA Litigation Settlementsjdsupra.com
- ANDA Litigation Settlements - Fall 2019jdsupra.com
- ANDA Litigation Settlements - Spring 2020jdsupra.com
- ANDA Litigation Settlements - Winter 2020jdsupra.com
- 2019 Year-End Biosimilar Litigation Roundupjdsupra.com
- ANDA Litigation Settlements - Summer 2019jdsupra.com
- November 2019: Patent Litigation Updatejdsupra.com
- Scheduling Order Entered in Amgen v. Adello Filgrastim Biosimilar Litigationjdsupra.com
- Biosimilar Litigation Trends and Lessons Learned in 2019jdsupra.com
- DOJ and FTC Propose Vertical Merger Guidelinesjdsupra.com